Genome-wide copy number variation (CNV) in patients with autoimmune Addison's disease
1 Institute of Medicine, University of Bergen, 5021 Bergen, Norway
2 Department of Medicine, Haukeland University hospital, 5021 Bergen, Norway
3 Institute of Clinical Medicine, University of Bergen, 5021 Bergen, Norway
4 Department of Medical Genetics, Haukeland University hospital, 5021 Bergen, Norway
BMC Medical Genetics 2011, 12:111 doi:10.1186/1471-2350-12-111Published: 18 August 2011
Addison's disease (AD) is caused by an autoimmune destruction of the adrenal cortex. The pathogenesis is multi-factorial, involving genetic components and hitherto unknown environmental factors. The aim of the present study was to investigate if gene dosage in the form of copy number variation (CNV) could add to the repertoire of genetic susceptibility to autoimmune AD.
A genome-wide study using the Affymetrix GeneChip® Genome-Wide Human SNP Array 6.0 was conducted in 26 patients with AD. CNVs in selected genes were further investigated in a larger material of patients with autoimmune AD (n = 352) and healthy controls (n = 353) by duplex Taqman real-time polymerase chain reaction assays.
We found that low copy number of UGT2B28 was significantly more frequent in AD patients compared to controls; conversely high copy number of ADAM3A was associated with AD.
We have identified two novel CNV associations to ADAM3A and UGT2B28 in AD. The mechanism by which this susceptibility is conferred is at present unclear, but may involve steroid inactivation (UGT2B28) and T cell maturation (ADAM3A). Characterization of these proteins may unravel novel information on the pathogenesis of autoimmunity.